Strides Arcolab Inks Deal With Gilead Sciences for HIV Drug

Indian pharmaceutical company Strides Arcolab has entered into a licensing agreement with US-based Gilead Sciences to manufacture and distribute latter's low-cost HIV drug, Tenofovir Alafenamide (TAF), in developing countries.

In a BSE filing, Strides Arcolab said, "It has entered into a licensing agreement with Gilead Sciences, Inc under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs."

Drug Resistance – Antibiotic or Antimicrobial Resistance
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and hospital acquired diseases. Judicious use of antibiotics can control the problem.

Strides said that the license being granted to it extends to 112 countries.

"Strides will receive technology transfer from Gilead, enabling Strides to manufacture low cost versions of TAF for developing countries," the company stated.

TAF is an investigational product in the US and have not yet been determined safe and efficacious in humans.

Bone Metastases in Prostate Cancer Blocked by HIV Drug
While most men with prostate cancer can be successfully treated, when the disease metastasizes to the bone, it eventually becomes lethal.

Source-Medindia

Vision Loss can be Stopped With Help of HIV Drugs
Study has revealed that drugs used for HIV virus and AIDS treatment can help fight loss of vision.

Altered Milk Protein can Deliver HIV Drug to Infants and Young Children
A novel method of altering a protein in milk to bind with an antiretroviral drug promises to greatly improve treatment for infants and young children suffering from HIV/AIDS.